New Study Shows Neurotechnology Combined with Saliva Testing Increases Accuracy in Detecting Cannabis Psychoactive Effects

A recent study revealed how combining neurotechnology with saliva testing can reduce the chances of falsely claiming cannabis impairment due to THC.

A study released in the scientific journal Advances in Therapy explained that when combining neurotechnology with saliva testing, it can drastically reduce the chances of falsely claiming cannabis impairment due to tetrahydrocannabinol (THC) residual detection (1). The research from this blind study was performed by KGK Science on behalf of Zentrela.

Not much is known on the effects of the brain caused from cannabis psychoactive properties or how accurate those effects can be measured. Saliva, blood, and urine have been the traditional methods used by law enforcement and employers to detect and quantify THC-compound levels. It is well recognized that there is no direct correlation between THC concentration levels in bodily fluids and if an individual is experiencing psychoactive effects associated with THC. This creates an issue because employers and law enforcement agencies are unable to confirm impairment in an individual, which leads to the possibility of inaccurate determinations of cannabis impairment. False determinations can negatively affect the reputation and employment of individuals who may be consuming legal cannabis products responsibly.

In KGK Sciences’ study, the data illustrates how Zentrela’s Cognalyzer neurotechnology can detect and quantify the psychoactive effects of cannabis. The data further highlights that neurotechnology, when combined with an oral fluid test used for detecting and assessing THC levels, immensely improves the accuracy of testing and decreases the chances of falsely claiming cannabis impairment due to THC residual detection.

Zentrela will now be collaborating with strategic research partners to correlate its objective cannabis psychoactive effect scale with cognitive performance data used to specify a psychoactive effect level which indicates when it is not advisable for cannabis consumers to work or drive a vehicle.

“The ability to definitively measure the psychoactive effects of cannabis allows us to begin addressing the problems related to cannabis consumption that affect the industry and the broader community,” said Dr. Dan Bosnyak the Chief Science Officer at Zentrela (2,3). “A scientifically objective cannabis psychoactive-effect test has endless applications for cannabis producers and product manufacturers, for law enforcement, and for employers in many industries.”

Having an accessible scientific database of cannabis product effects also solves one of the many challenges plaguing producers and brands in the recreational cannabis industry, which is the availability of regulatory-compliant cannabis effect data.

“Without this information, producers cannot differentiate their products and inform consumers about the different effects created by their recreational cannabis products, retailers cannot meet their CANCELL mandate to educate consumers and promote responsible cannabis use and, of course, consumers are missing out on the information that they require to make more accurate and informed decisions about recreational cannabis consumption,” said Israel Gasperin the CEO of Zentrela (2,3). “The data we are generating will give retailers and producers access to a centralized source of scientifically-derived product effect information, which will benefit the entire cannabis industry value chain.”

Gasperin further added that until now there has not been an accurate, scientific-based test for quantifying the psychoactive effects of cannabis. “We have clearly demonstrated that neuroscience powered by artificial intelligence (AI) can accurately detect and quantify the psychoactive effects of cannabis,” said Gasperin. “This represents a huge potential for Zentrela to become the definitive source for specific, science-based data on cannabis product effects for the entire industry. And we are still at the beginning of our journey. There is no reason we cannot apply this proven neurotechnology to other drugs and industries.”

By combining neurotechnology and saliva testing, it will help ease some of the conflict that arises for not just law enforcement and employers, but consumers as well.

References

  1. https://link.springer.com/article/10.1007/s12325-021-01718-6
  2. https://finance.yahoo.com/news/neurotechnology-combined-saliva-testing-boosts-140500087.html
  3. https://www.news-medical.net/news/20210407/Neurotechnology-combined-with-saliva-testing-improves-accuracy-in-measuring-psychoactive-effects-of-cannabis.aspx